The clinical significance of β-arrestin 2 expression in the serum of non-small cell lung cancer patients

Chinese Journal of Lung Cancer

Volumn 14, Issue 6, 2011, Pages 497-501

  Wu, Zhengqing ^a   Tong, Wenxia ^a   Tan, Zihui ^a   Wang, Siyu ^a   Lin, Peng ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

arrestin 2; Lung neoplasms; Prognostic factors

Indexed keywords

BETA ARRESTIN 2;

ARTICLE; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

ADULT; AGED; ARRESTINS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS;

EID: 79958719332     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2011.06.04     Document Type: Article

References (15)

1. Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest, 2003, 123(1 Suppl): 21S-49S.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin, 2007, 57(1): 43-66.
3. Maione P, Rossi A, Sacco PC, et al. Advances in chemotherapy in advanced non-small-cell lung cancer. Expert Opin Pharmacother, 2010, 11(18): 2997-3007.
4. Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin Proc, 2008, 83(3): 355-367.
5. Little AG. No nodes is good nodes. Ann Thorac Surg, 2006, 82(1): 4-5.
6. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: updated 2003. J Clin Oncol, 2004, 22(2): 330-353.
7. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med, 2004, 350(4): 379-392.
8. Luker KE, Steele JM, Mihalko LA, et al. Constitutive and chemokine-dependent internalization and recycling of CXCR7 in breast cancer cells to degrade chemokine ligands. Oncogene, 2010, 29(32): 4599-4610.
9. Li TT, Alemayehu M, Aziziyeh AI, et al. Constitutive and chemokine-dependent internalization and recycling of CXCR7 in breast cancer cells to degrade chemokine ligands. Mol Cancer Res, 2009, 7(7): 1064-1077.
10. Lakshmikanthan V, Zou L, Kim JI, et al. Identification of betaArrestin2 as a corepressor of androgen receptor signaling in prostate cancer. Proc Natl Acad Sci USA, 2009, 106(23): 9379-9384
11. Gurevich VV, Gurevich EV. The structural basis of arrestin-mediated regulation of G-protein-coupled receptors. Pharmacol Ther, 2006, 110(3): 465-502.
12. Wang P, Gao H, Ni Y, et al. Beta-arrestin 2 functions as a G-protein-coupled receptor-activated regulator of oncoprotein Mdm2. J Biol Chem, 2003, 278(8): 6363-6370.
13. Raghuwanshi SK, Nasser MW, Chen X, et al. Depletion of beta-arrestin-2 promotes tumor growth and angiogenesis in a murine model of lung cancer. J Immunol, 2008, 180(8): 5699-5706.
14. Pfannschmidt J, Mulcy T, Bulzebruck H, et al. Prognostic assessment after surgical resection for non-small cell lung cancer: expriences in 2083 patients. Lung Cancer, 2007, 55(3): 371-377.
15. Liu SK, Xu SF, Luo BJ, et al. Multivariate analysis of prognosis in 1380 patients with non-small cell lung cancer following surgical procedure. Chin J Lung Cancer, 2006, 9(5): 465-468.